Benign Conditions

Benign Prostatic Hyperplasia

Bladder Cancer

Female Urology

Genitourinary Cancers

Genomic Testing

Hormone Therapy

Kidney Cancer

Challenging Anatomy

Innovative Techniques

Laser Lithotripsy

PCNL Tech & Devices

Ureteroscopy Tech & Devices

Kidney Stones

Men's Health

Next-Generation Imaging

Voiding Dysfunction

OAB and Incontinence

Pediatrics

Controveries in Urologic Cancer

Drug Therapy

Prostate Cancer

Sexual Dysfunction

UTUC

Cosmetic Surgery

Urologic Surgery

Business

Practice Management

Malpractice Consult

Health Law & Policy

Media

Case-Based Peer Perspectives

Investigator Perspectives 

Medical World News

Podcasts

Urology Medical Perspectives

UTv Videos

Peer Exchange

Special Report

Virtual Tumor Board

Insights

Medcast

Peers & Perspectives

Conferences

Conference Listing

Conference Previews 

Conference Recaps

Publications

Urology Times Journal

Editorial Advisory Board

Urologists in Cancer Care

Supplements and Featured Publications

Clinical Forums Recaps

CME/CE

Resources

Begin Your Journey: Tackling Burnout

Live Events

Interactive Tools

Job Board

Partners

Treatment Landscape Evolutions

Subscribe

Articles

Benjamin P. Saylor is associate editor of Urology Times, an Advanstar Communications publication.

View slated interviews with experts as well as insights from urologists on what to watch for. 

Conference Preview: American Urological Association 2025 

"In this large study of over 1500 men with an elevated PSA, we found that a low IsoPSA is incredibly reassuring,” says Christopher J. Weight, MD. 

Study shows IsoPSA’s predictive ability for clinically significant prostate cancer

Hugec is a medical oncologist and hematologist at Minnesota Oncology in Maplewood.

"We’ve achieved a lot, but the focus now must shift from cure alone to comprehensive, patient-centered care," says Vladimir Hugec, MD.

Testicular Cancer Awareness Month: Advances and controversies in testicular cancer care 

Take a look through several of the notable phase 3 trials in progress that will be spotlighted at AUA 2025. 

10 urology trials in progress to be highlighted at AUA 2025

Urology Times is the leading resource for urologists & allied health professionals offering clinical analysis, policy perspectives, & practical advice.

About Us

Advertise

Editorial

Contact Us

Terms and Conditions

Privacy

Do not sell my Personnal Information

Urology Times | News & Insights for Urologists & Health Professionals

Facebook

LinkedIn

Spotlight

Peers and Perspectives

Clinical

1rem

View

Optimizing Sequential Therapy in Metastatic Castration-Resistant Prostate Cancer (mCRPC) with Bone-Predominant Disease

Video Series

Case 1: A 68-Year-Old Man with Bone-Predominant Metastatic Castration-Resistant Prostate Cancer (mCRPC)  

Videos

Dr. De La Cerda provides an overview of a patient case involving a 68 year-old male presenting with severe back pain, with an analysis of the clinical presentation, workup, and medical history.

Bone Predominant mCRPC Patient Case

This video segment explores how to choose between the original brand, generic, and micronized versions of abiraterone, considering factors like efficacy, cost, patient preference, and clinical context.

Abiraterone Acetate Versions for Treatment of mCRPC

This video segment discusses patient selection criteria for choosing between the original brand, generic, and micronized versions of abiraterone.

Patient Selection Criteria for Different Versions of Abiraterone Acetate in mCRPC

This video segment covers patient selection criteria for different versions of abiraterone, strategies for assessing treatment efficacy and safety, engaging caregivers to monitor compliance and side effects, and navigating insurance challenges to ensure patients receive the recommended version.

Assessing Treatment Efficacy: Communication with Patients and Caregivers

This video segment discusses the frequency of encountering mCRPC patients with hepatic dysfunction, additional tests to consider, and treatment options for these patients.

Patient with mCRPC and Hepatic Disease

This video segment explores treatment approaches for PSMA-positive mCRPC patients, algorithms for monitoring liver dysfunction in advanced CRPC, and exciting advancements in mCRPC treatment.

Treatment and Co-Management of mCRPC Patients with Aggressive Disease

Case Based Peer Perspectives

Case 1: A 68-Year-Old Man with Bone-Predominant Metastatic Castration-Resistant Prostate Cancer (mCRPC)

EP: 1.Bone Predominant mCRPC Patient Case

EP: 2.Case 1: A 68-Year-Old Man with Bone-Predominant Metastatic Castration-Resistant Prostate Cancer (mCRPC)

EP: 3.Abiraterone Acetate Versions for Treatment of mCRPC

EP: 4.Patient Selection Criteria for Different Versions of Abiraterone Acetate in mCRPC

EP: 5.Assessing Treatment Efficacy: Communication with Patients and Caregivers

EP: 6.Patient with mCRPC and Hepatic Disease

EP: 7.Treatment and Co-Management of mCRPC Patients with Aggressive Disease